Radiopharmaceutical therapy of chronic inflammatory knee joint disease
Phase 3
- Conditions
- Rheumatoid arthritis of knee joint.Seropositive rheumatoid arthritis
- Registration Number
- IRCT201112251100N4
- Lead Sponsor
- uclear Science and Technology Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Patients (>20 yr) with chronic arthritis of knee joint who have the following characteristics including chronic knee pain with no treatment response to NSAIDS and DMARDs for three months, positive blood pool phase in bone scan, absence of Baker cyst in ultrasond, absence of pregnancy and breastfeeding, no intra-articular injection of corticosteroids in the past 6 weeks, absence of knee surgery in the past 8 weeks, no removal of synovial fluid in the past 2 weeks, no severe damage or traumato the knee joint, absence of skin infection at the injection site. Exclusion criteria: improper injection of radiopharmaceutical and Lack of patient cooperation during the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical assessment of the patients. Timepoint: 1, 3 and 6 months after radiopharmaceutical injection. Method of measurement: Standardized questionaire.
- Secondary Outcome Measures
Name Time Method Analgesic consumption. Timepoint: 1, 3 and 6 months after radiopharmaceutical injection. Method of measurement: Questionnaire.